-
SAB Biotherapeutics to Host Virtual 2022 Annual R&D Portfolio Update (opens in a new tab)
SIOUX FALLS, S.D., Aug. 04, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS), a clinical-stage biopharmaceutical company with a first of its…
-
SAB Biotherapeutics Announces Election of Rear Admiral (retired) Scott Giberson, RPh, MPH, D.Sc., to Board of Directors (opens in a new tab)
SIOUX FALLS, S.D., July 11, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel…
-
SAB Biotherapeutics Hosts U.S. Representatives Dusty Johnson and Dean Phillips for South Dakota Facility Tour (opens in a new tab)
SIOUX FALLS, S.D., July 05, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB, or “the Company”), a clinical-stage biopharmaceutical…
-
SAB Biotherapeutics Announces Appointment of Alexandra Kropotova, M.D., as Chief Medical Officer (opens in a new tab)
SIOUX FALLS, S.D., June 06, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel…
-
SAB Biotherapeutics Chief Operating Officer, Dr. Christoph Bausch, to Present at the Large Animal Genetic Engineering Summit (opens in a new tab)
In-person presentation titled ‘Leveraging Genetically Engineered Ungulates to Produce Novel Human Biotherapeutics’ to take place on June 7 in Park City,…
-
SAB Biotherapeutics Provides Company Update for Q1 2022 Financial Results (opens in a new tab)
Full data from Phase 2a trial that evaluated SAB-176 for treatment of seasonal influenza expected third quarter 2022 – first clinical data set from novel…
-
SAB Biotherapeutics to Present at 2022 H.C. Wainwright Global Investment Conference (opens in a new tab)
SIOUX FALLS, S.D., May 12, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS), announced today its participation at the H.C. Wainwright Global…
-
SAB Biotherapeutics Appoints Mark J. Ratain, MD, to the Company’s Board of Scientific Advisors (opens in a new tab)
SIOUX FALLS, S.D., April 05, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a…
-
SAB Biotherapeutics Provides Company Update and Reports Full Year 2021 Financial Results (opens in a new tab)
SAB executing on its strategy to build a proprietary immune and autoimmune disorders pipeline, including respiratory diseases that affect…
-
SAB Biotherapeutics Reports NIH is Discontinuing Phase 3 ACTIV-2 Trial Assessing SAB-185 for Treatment of COVID-19 Due to Declining COVID Hospitalizations (opens in a new tab)
NIH is closing enrollment in its ACTIV-2 trial due to low Omicron-related COVID-19 hospitalization and death rates that have made the current study…
-
SAB Biotherapeutics Announces Publication of Nonclinical Data Demonstrating SAB-185 Has High Potency for Effectively Neutralizing Circulating and Emerging SARS-CoV-2 Variants (opens in a new tab)
In the FDA-conducted study , SAB-185 consistently demonstrated high avidity and high potency for effectively neutralizing a broad range of SARS-CoV-2…
-
SAB Biotherapeutics Announces Update to the Phase 3 NIH ACTIV-2 Trial Design Evaluating SAB-185 for Treatment of COVID-19 (opens in a new tab)
ACTIV-2 Phase 3 trial continuing as placebo-controlled study in Omicron variant COVID participants SIOUX FALLS, S.D., Feb. 25, 2022 (GLOBE NEWSWIRE) --…